Top ▲

Hereditary angioedema

Disease ID:1218
Name:Hereditary angioedema
Associated with:0 target
2 immuno-relevant ligands
Hereditary angioedema is an autosomal dominant disorder characterized by episodic local subcutaneous edema and submucosal edema involving the upper respiratory and gastrointestinal tracts. Mutations in two genes underlie the sub-classification of HAE types I and II (heterozygous mutation in the C1 inhibitor gene) and HAE type III (mutation in the coagulation factor XII (F12) gene.
Database Links
Disease Ontology: DOID:14735
OMIM: 106100, 610618


No target related data available for Hereditary angioedema


Key to terms and symbols Click ligand name to view ligand summary Click column headers to sort
Ligand References Clinical and Disease comments
Immuno Disease Comments: Approved drug for HAE.
Clinical Use: Icatibant has been approved to treat hereditary angiodema (HAE). The drug is under investigation for other conditions susceptible to bradykinin amelioration eg ACE inhibitor-induced angiodema, knee ostoearthritis and use during cardiopulmonary bypass surgery. Click here to link to's records for this drug. | View clinical data
Immuno Disease Comments: Approved for HAE in adults and children >12 years of age.
Clinical Use: Ecallantide is used to treat adults who suffer attacks of hereditary angioedema (HAE, an immune system disorder) [1]. The drug acts to suppress the tissue swelling associated with hereditary angioedema. As of April 2014, children 12 years and older may be given this drug to treat HAE attacks. | View clinical data
Bioactivity Comments: We have been unable to find publicly available bioactivity data for this drug at its proposed molecular target to substantiate its MMOA, and have therefore not tagged a primary drug target. | View biological activity


Show »

1. Cicardi M, Levy RJ, McNeil DL, Li HH, Sheffer AL, Campion M, Horn PT, Pullman WE. (2010) Ecallantide for the treatment of acute attacks in hereditary angioedema. N. Engl. J. Med., 363 (6): 523-31. [PMID:20818887]